Methods to evaluate and improve the injection site tolerability of intravenous formulations prior to first-in-human testing

Journal of Pharmacological and Toxicological Methods

Volumn 68, Issue 3, 2013, Pages 394-406

  Eichenbaum, G ^a   Zhou, J ^a   De Smedt, A ^b   De Jonghe, S ^b   Looszova, A ^b   Arien, T ^b   Van Goethem, F ^b   Vervoort, I ^b   Shukla, U ^a   Lammens, L ^b  

^a JOHNSON AND JOHNSON   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Decision tree; Infusion site; Intravenous; Irritation; Low solubility; Precipitation

Indexed keywords

CYCLODEXTRIN; DRUG; EXCIPIENT; JNJ X; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DOG; DRUG FORMULATION; DRUG SOLUBILITY; DRUG TOLERABILITY; FEMALE; INJECTION SITE IRRITATION; INJECTION SITE REACTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PH; RABBIT; RAT; TOXICITY TESTING;

CANIS FAMILIARIS; ORYCTOLAGUS CUNICULUS; RATTUS;

DECISION TREE; INFUSION SITE; INTRAVENOUS; IRRITATION; LOW SOLUBILITY; PRECIPITATION;

ANIMALS; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; COMPUTER SIMULATION; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUGS, INVESTIGATIONAL; EXCIPIENTS; FEMALE; HYDROGEN-ION CONCENTRATION; INFUSIONS, INTRAVENOUS; MALE; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SPECIES SPECIFICITY; TOXICITY TESTS;

EID: 84886415587     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2013.08.002     Document Type: Article

References (34)

1. Armbruster C., Robibaro B., Griesmacher A., Vorbach H. Endothelial cell compatibility of trovafloxacin and levofloxacin for intravenous use. Journal of Antimicrobial Chemotherapy 2000, 45:533-535.
2. Brewster M.E., Anderson W.R., Loftsson T., Huang M.J., Bodor N., Pop E. Preparation, characterization, and anesthetic properties of 2-hydroxypropyl-beta-cyclodextrin complexes of pregnanolone and pregnenolone in rat and mouse. Journal of Pharmaceutical Sciences 1995, 84:1154-1159.
3. Dai W.G. In vitro methods to assess drug precipitation. International Journal of Pharmaceutics 2010, 393:1-16.
4. Davio S.R., McShane M.M., Kakuk T.J., Zaya R.M., Cole S.L. Precipitation of the renin inhibitor ditekiren upon i.v. infusion; in vitro studies and their relationship to in vivo precipitation in the cynomolgus monkey. Pharmaceutical Research 1991, 8:80-83.
5. Diehl K.H., Hull R., Morton D., Pfister R., Rabemampianina Y., Smith D., Vidal J.M., van de Vorstenbosch C., European Federation of Pharmaceutical Industries A., European Centre for the Validation of Alternative M. A good practice guide to the administration of substances and removal of blood, including routes and volumes. Journal of Applied Toxicology 2001, 21:15-23.
6. Gautheron P., Dukic M., Alix D., Sina J.F. Bovine corneal opacity and permeability test: An in vitro assay of ocular irritancy. Fundamental and Applied Toxicology 1992, 18:442-449.
7. Gilleron L., Coecke S., Sysmans M., Hansen E., Van Oproy S., Marzin D., Van Cauteren H., Vanparys P. Evaluation of a modified HET-CAM assay as a screening test for eye irritancy. Toxicology In Vitro 1996, 10:431-446.
8. Hoover D.M., Gardner J.B., Timmerman T.L., Klepfer J.A., Laska D.A., White S.L., et al. Comparison of in vitro and in vivo models to assess venous irritation of parenteral antibiotics. Fundamental and Applied Toxicology 1990, 14:589-597.
9. Hull R.M. Guideline limit volumes for dosing animals in the preclinical stage of safety evaluation. Toxicology subcommittee of the Association of the British Pharmaceutical Industry. Human and Experimental Toxicology 1995, 14:305-307.
10. ICH-M3(R2) International conference on harmonization: Non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals 2009, (http://www.fda.gov/cder/guidance/index.htm).
11. Jankovic B.D., Isakovic K., Lukic M.L., Vujanovic N.L., Petrovic S., Markovic B.M. Immunological capacity of the chicken embryo. I. Relationship between the maturation of lymphoid tissues and the occurrence of cell-mediated immunity in the developing chicken embryo. Immunology 1975, 29:497-508.
12. Johnson J.L., He Y., Yalkowsky S.H. Prediction of precipitation-induced phlebitis: A statistical validation of an in vitro model. Journal of Pharmaceutical Sciences 2003, 92:1574-1581.
13. Kipp J. Solvent systems and their selection in pharmaceutics and biopharmaceutics. Solvent systems and their selection in pharmaceutics and biopharmaceutics 2007, 309-339. Springer New York, New York. P. Augustijns, M. Brewster (Eds.).
14. Kohno E., Murase S., Matsuyama K., Okamura N. Effect of corticosteroids on phlebitis induced by intravenous infusion of antineoplastic agents in rabbits. International Journal of Medical Sciences 2009, 6:218-223.
15. Kuwahara T., Asanami S., Kubo S. Experimental infusion phlebitis: Tolerance osmolality of peripheral venous endothelial cells. Nutrition 1998, 14:496-501.
16. Lawrence R.S., Groom M.H., Ackroyd D.M., Parish W.E. The chorioallantoic membrane in irritation testing. Food and Chemical Toxicology 1986, 24:497-502.
17. Lee Y.C., Zocharski P.D., Samas B. An intravenous formulation decision tree for discovery compound formulation development. International Journal of Pharmaceutics 2003, 253:111-119.
18. Lemez L. Thrombocytes of chick embryos from the 2nd day of incubation till the 1st postembryonic day. Acta Universitatis Carolinae. Medica. Monographia 1972, 53:365-371.
19. Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. Journal of Pharmaceutical Sciences 1996, 85:1017-1025.
20. Luepke N.P. Hen's egg chorioallantoic membrane test for irritation potential. Food and Chemical Toxicology 1985, 23:287-291.
21. Maksimov V.F., Korostyshevskaya I.M., Kurganov S.A. Functional morphology of chorioallantoic vascular network in chicken. Bulletin of Experimental Biology and Medicine 2006, 142:367-371.
22. McCandless R., Yalkowsky S.H. Effect of hydroxypropyl-beta-cyclodextrin and pH on the solubility of levemopamil HCl. Journal of Pharmaceutical Sciences 1998, 87:1639-1642.
23. Nuijen B., Bouma M., Henrar R.E., Brauns U., Bette P., Bult A., et al. In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS. International Journal of Pharmaceutics 2000, 194:261-267.
24. Overbeck H.W., Daugherty R.M., Haddy F.J. Continuous infusion indicator dilution measurement of limb blood flow and vascular response to magnesium sulfate in normotensive and hypotensive men. The Journal of Clinical Investigation 1969, 48:1944-1957.
25. Parish W.E. Ability of in vitro (corneal injury-eye organ-and chorioallantoic membrane) tests to represent histopathological features of acute eye inflammation. Food and Chemical Toxicology 1985, 23:215-227.
26. Portmann G.A., Simmons D.M. Microscopic determination of drug solubility in plasma and calculation of injection rates with a plasma circulatory model to prevent precipitation on intravenous injection. Journal of Pharmaceutical and Biomedical Analysis 1995, 13:1189-1193.
27. Schindler S., Spreitzer I., Loschner B., Hoffmann S., Hennes K., Halder M., et al. International validation of pyrogen tests based on cryopreserved human primary blood cells. Journal of Immunological Methods 2006, 316:42-51.
28. Spielmann H., Gerner I., Kalweit S., Moog R., Wirnsberger T., Krauser K., Kreiling R., Kreuzer H., Lupke N.P., Miltenburger H.G., Muller N., Murmann P., Pape W., Siegemund B., Spengler J., Steiling W., Wiebel F.J. Interlaboratory assessment of alternatives to the Draize eye irritation test in Germany. Toxicology In Vitro 1991, 5:539-542.
29. Spielmann H., Kalweit S., Liebsch M., Wirnsberger T., Gerner I., Bertram-Neis E., Krauser K., Kreiling R., Miltenburger H.G., Pape W., Steiling W. Validation study of alternatives to the Draize eye irritation test in Germany: Cytotoxicity testing and HET-CAM test with 136 industrial chemicals. Toxicology In Vitro 1993, 7:505-510.
30. Stella V.J., He Q. Cyclodextrins. Toxicologic Pathology 2008, 36:30-42.
31. Turner P.V., Pekow C., Vasbinder M.A., Brabb T. Administration of substances to laboratory animals: Equipment considerations, vehicle selection, and solute preparation. Journal of the American Association for Laboratory Animal Science 2011, 50:614-627.
32. Vorbach H., Weigel G., Robibaro B., Schaumann R., Hlousek M., Beil W.J., et al. Endothelial cell compatibility of fluoroquinolone solutions for intravenous use. International Journal of Clinical Pharmacology & Therapeutics 1997, 35:235-238.
33. Weber K., Mowat V., Hartmann E., Razinger T., Chevalier H.J., Blumbach K., et al. Pathology in continuous infusion studies in rodents and non-rodents and ito (Infusion TECHNOLOGY organisation)-recommended protocol for tissue sampling and terminology for procedure-related lesions. Journal of Toxicologic Pathology 2011, 24:113-124.
34. Yalkowsky S.H., Krzyzaniak J.F., Ward G.H. Formulation-related problems associated with intravenous drug delivery. Journal of Pharmaceutical Sciences 1998, 87:787-796.